Cubist Systematic Strategies’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-67,228
| Closed | -$2.32M | – | 2810 |
|
|
2020
Q3 | $2.32M | Buy |
67,228
+51,535
| +328% | +$1.1M | 0.03% | 816 |
|
|
2020
Q2 | $262K | Sell |
15,693
-46,396
| -75% | -$788K | ﹤0.01% | 1907 |
|
|
2020
Q1 | $895K | Buy |
+62,089
| New | +$1.59M | 0.02% | 898 |
|
|
2019
Q3 | – | Sell |
-25,879
| Closed | -$539K | – | 2620 |
|
|
2019
Q2 | $539K | Buy |
+25,879
| New | +$533K | 0.01% | 1432 |
|
|
2018
Q4 | – | Sell |
-6,736
| Closed | -$184K | – | 2379 |
|
|
2018
Q3 | $184K | Buy |
+6,736
| New | +$191K | 0.01% | 1441 |
|
|
2018
Q2 | – | Sell |
-49
| Closed | -$2K | – | 2162 |
|
|
2018
Q1 | $2K | Sell |
49
-2,251
| -98% | -$79.2K | ﹤0.01% | 1799 |
|
|
2017
Q4 | $87K | Buy |
2,300
+2,199
| +2,177% | +$71K | ﹤0.01% | 1705 |
|
|
2017
Q3 | $3K | Buy |
+101
| New | +$2.18K | ﹤0.01% | 1808 |
|
|
2017
Q2 | – | Sell |
-1,300
| Closed | -$28K | – | 1963 |
|
|
2017
Q1 | $28K | Sell |
1,300
-794
| -38% | -$16.3K | ﹤0.01% | 1530 |
|
|
2016
Q4 | $43K | Buy |
+2,094
| New | +$42.8K | ﹤0.01% | 1596 |
|
Cubist Systematic Strategies's AIMT Position: Q4 2020 in Review
Cubist Systematic Strategies sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 67,228 shares — an estimated $2.32M sold.
Cubist Systematic Strategies first reported a position in AIMT in Q4 2016 and held it in 10 quarters. The position peaked at $2.32M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Cubist Systematic Strategies reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Cubist Systematic Strategies sold 67,228 Aimmune Therapeutics shares in Q4 2020, an estimated $2.32M.
- Cubist Systematic Strategies first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 10 quarters.
- Cubist Systematic Strategies's Aimmune Therapeutics position peaked at $2.32M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Cubist Systematic Strategies's 13F filing for Q4 2020, filed 16 Feb 2021.